Safety and efficacy of MT10107 in post-stroke upper limb spasticity treatment A phase I randomized controlled trial

Junekyung Lee, Min Ho Chun, Young Jin Ko, Shi Uk Lee, Deog Young Kim, Nam Jong Paik

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Botulinum toxin type A injection is widely used treatment option for the treatment of upper limb spasticity in stroke patients. The purpose of this study was to explore the safety and efficacy of MT10107, a new botulinum toxin type A, in patients with post-stroke upper limb spasticity. Methods: A prospective, randomized, double-blind, active drug-controlled, multi-center, phase I clinical trial. Thirty patients with post-stroke upper limb spasticity were received either MT10107 or onabotulinumtoxinA. Primary endpoint was change of modified Ashworth scale (MAS) score for wrist flexor from baseline to week 4. The secondary endpoints were changes of MAS scores for elbow and finger flexors, response rate, Disability Assessment Scale (DAS), and global assessment of treatment. The safety endpoints such as adverse events, vital signs, physical examination, and laboratory test were evaluated. The outcome measures were evaluated from baseline to week 4. Results: The primary endpoints were −1.07±0.70 and −1.23±0.56 for the MT10107 and onabotulinumtoxinA groups, respectively. The intergroup difference of change between the 2 groups was 0.17 (95% confidence interval −0.31 to 0.64, P = .5769). In secondary endpoints, both groups showed a significant improvement in both MAS and DAS. There was no significant between-group difference in all secondary endpoints and safety measures. Conclusion: The safety and efficacy of MT10107 showed no significant difference compared to onabotulinumtoxinA in poststroke upper limb spasticity treatment.

Original languageEnglish
Pages (from-to)E31367
JournalMedicine (United States)
Volume101
Issue number44
DOIs
StatePublished - 4 Nov 2022

Keywords

  • botulinum toxins
  • muscle spasticity
  • safety
  • stroke
  • upper extremity

Fingerprint

Dive into the research topics of 'Safety and efficacy of MT10107 in post-stroke upper limb spasticity treatment A phase I randomized controlled trial'. Together they form a unique fingerprint.

Cite this